← Leaderboards
Wyndham H Wilson
Clinical Sciences
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Dose”
- Lawrence Corey · Fred Hutchinson Cancer Center$251,944,397
- Sharon A Nachman · Johns Hopkins University$213,337,729
- David Heimbrook · Leidos Biomedical Research, Inc.$146,807,554
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$134,297,561
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$124,321,134
- Peter C Adamson · National Childhood Cancer Foundation$122,197,823
Research focus
DoseS LymphomaLarge Cell Diffuse Non-Hodgkin&AposTumorB-LymphocytesBaseNf-Kappa BLymphomaRefractoryChemotherapyToxic EffectRelapseCellsResponseMolecularRegimenPathway InteractionsSafetyPharmaceutical PreparationsBortezomibPharmacodynamicsIn VitroApoptosisMutation
Grant awards (112)
Therapeutic Strategies and Molecular Correlates in Aggressive B-cell Lymphomas$839,920
ZIA · FY2025 · CA · contact PI
Targeted treatment of B-cell Lymphoma$839,920
ZIA · FY2025 · CA · contact PI
Therapeutic Strategies and Molecular Correlates in Aggressive B-cell Lymphomas$780,978
ZIA · FY2024 · CA · contact PI
Targeted treatment of B-cell Lymphoma$780,978
ZIA · FY2024 · CA · contact PI
Targeted treatment of B-cell Lymphoma$745,944
ZIA · FY2023 · CA · contact PI
Therapeutic Strategies and Molecular Correlates in Aggressive B-cell Lymphomas$745,944
ZIA · FY2023 · CA · contact PI
Therapeutic Strategies and Molecular Correlates in Aggressive B-cell Lymphomas$607,425
ZIA · FY2022 · CA · contact PI
Targeted treatment of B-cell Lymphoma$607,425
ZIA · FY2022 · CA · contact PI
Lymphoma Studies$667,177
ZIA · FY2021 · CA · contact PI
TEDDI-R in PCNSL$200,154
ZIA · FY2021 · CA · contact PI
Randomized Phase II study of borteozmib-EPOCH-R in Mantle cell lymphoma$133,435
ZIA · FY2021 · CA · contact PI
BCR Signaling in ABC DLBCL$133,435
ZIA · FY2021 · CA · contact PI
Phase I study of bortezomib and DA-EPOCH-R with microarray in DLBCL$133,435
ZIA · FY2021 · CA · contact PI
Phase III Study of R-CHOP v DA-EPOCH-R with microarray$66,718
ZIA · FY2021 · CA · contact PI
Lymphoma Studies$707,482
ZIA · FY2020 · CA · contact PI
TEDDI-R in PCNSL$212,244
ZIA · FY2020 · CA · contact PI
Randomized Phase II study of borteozmib-EPOCH-R in Mantle cell lymphoma$141,496
ZIA · FY2020 · CA · contact PI
BCR Signaling in ABC DLBCL$141,496
ZIA · FY2020 · CA · contact PI
Phase I study of bortezomib and DA-EPOCH-R with microarray in DLBCL$141,496
ZIA · FY2020 · CA · contact PI
Phase III Study of R-CHOP v DA-EPOCH-R with microarray$70,749
ZIA · FY2020 · CA · contact PI
Lymphoma Studies$681,876
ZIA · FY2019 · CA · contact PI
TEDDI-R in PCNSL$204,562
ZIA · FY2019 · CA · contact PI
Randomized Phase II study of borteozmib-EPOCH-R in Mantle cell lymphoma$136,375
ZIA · FY2019 · CA · contact PI
BCR Signaling in ABC DLBCL$136,375
ZIA · FY2019 · CA · contact PI
Phase I study of bortezomib and DA-EPOCH-R with microarray in DLBCL$136,375
ZIA · FY2019 · CA · contact PI
Phase III Study of R-CHOP v DA-EPOCH-R with microarray$68,187
ZIA · FY2019 · CA · contact PI
Lymphoma Studies$795,122
ZIA · FY2018 · CA · contact PI
TEDDI-R in PCNSL$238,537
ZIA · FY2018 · CA · contact PI
Randomized Phase II study of borteozmib-EPOCH-R in Mantle cell lymphoma$159,025
ZIA · FY2018 · CA · contact PI
BCR Signaling in ABC DLBCL$159,025
ZIA · FY2018 · CA · contact PI
Phase I study of bortezomib and DA-EPOCH-R with microarray in DLBCL$159,025
ZIA · FY2018 · CA · contact PI
Phase III Study of R-CHOP v DA-EPOCH-R with microarray$79,512
ZIA · FY2018 · CA · contact PI
Lymphoma Studies$677,573
ZIA · FY2017 · CA · contact PI
TEDDI-R in PCNSL$203,271
ZIA · FY2017 · CA · contact PI
Randomized Phase II study of borteozmib-EPOCH-R in Mantle cell lymphoma$135,515
ZIA · FY2017 · CA · contact PI
BCR Signaling in ABC DLBCL$135,515
ZIA · FY2017 · CA · contact PI
Phase I study of bortezomib and DA-EPOCH-R with microarray in DLBCL$135,515
ZIA · FY2017 · CA · contact PI
Phase III Study of R-CHOP v DA-EPOCH-R with microarray$67,758
ZIA · FY2017 · CA · contact PI
Lymphoma Studies$782,468
ZIA · FY2016 · CA · contact PI
TEDDI-R in PCNSL$234,740
ZIA · FY2016 · CA · contact PI
Randomized Phase II study of borteozmib-EPOCH-R in Mantle cell lymphoma$156,494
ZIA · FY2016 · CA · contact PI
BCR Signaling in ABC DLBCL$156,494
ZIA · FY2016 · CA · contact PI
Phase I study of bortezomib and DA-EPOCH-R with microarray in DLBCL$156,494
ZIA · FY2016 · CA · contact PI
Phase III Study of R-CHOP v DA-EPOCH-R with microarray$78,247
ZIA · FY2016 · CA · contact PI
Lymphoma Studies$728,259
ZIA · FY2015 · CA · contact PI
TEDDI-R in PCNSL$218,477
ZIA · FY2015 · CA · contact PI
Randomized Phase II study of borteozmibEPOCH-R in Mantle cell lymphoma$145,652
ZIA · FY2015 · CA · contact PI
BCR Signaling in ABC DLBCL$145,652
ZIA · FY2015 · CA · contact PI
Phase I study of bortezomib and DA-EPOCH-R with microarray in DLBCL$145,652
ZIA · FY2015 · CA · contact PI
Phase III Study of R-CHOP v DA-EPOCH-R with microarray$72,826
ZIA · FY2015 · CA · contact PI
Lymphoma Studies$704,359
ZIA · FY2014 · CA · contact PI
Phase III Study of R-CHOP v DA-EPOCH-R with microarray$281,743
ZIA · FY2014 · CA · contact PI
Randomized Phase II study of borteozmibEPOCH-R in Mantle cell lymphoma$140,872
ZIA · FY2014 · CA · contact PI
BCR Signaling in ABC DLBCL$140,872
ZIA · FY2014 · CA · contact PI
Phase I study of bortezomib and DA-EPOCH-R with microarray in DLBCL$140,872
ZIA · FY2014 · CA · contact PI
Lymphoma Studies$300,893
ZIA · FY2013 · CA · contact PI
Phase I and II Study of BCL Family Inhibitors in Lymphoma$200,595
ZIA · FY2013 · CA · contact PI
Phase II study of flavopiridol in mantle cell lymphoma and DLBCL$100,298
ZIA · FY2013 · CA · contact PI
Phase III Study of R-CHOP v DA-EPOCH-R with microarray$100,298
ZIA · FY2013 · CA · contact PI
Randomized Phase II study of borteozmibEPOCH-R in Mantle cell lymphoma$100,298
ZIA · FY2013 · CA · contact PI
Phase I study of bortezomib and DA-EPOCH-R with microarray in DLBCL$100,298
ZIA · FY2013 · CA · contact PI
BCR Signaling in ABC DLBCL$100,298
ZIA · FY2013 · CA · contact PI
Lymphoma Studies$332,649
ZIA · FY2012 · CA · contact PI
Phase I and II Study of BCL Family Inhibitors in Lymphoma$221,766
ZIA · FY2012 · CA · contact PI
Phase II study of flavopiridol in mantle cell lymphoma and DLBCL$110,883
ZIA · FY2012 · CA · contact PI
BCR Signaling in ABC DLBCL$110,883
ZIA · FY2012 · CA · contact PI
Phase III Study of R-CHOP v DA-EPOCH-R with microarray$110,883
ZIA · FY2012 · CA · contact PI
Randomized Phase II study of borteozmibEPOCH-R in Mantle cell lymphoma$110,883
ZIA · FY2012 · CA · contact PI
Phase I study of bortezomib and DA-EPOCH-R with microarray in DLBCL$110,883
ZIA · FY2012 · CA · contact PI
Lymphoma Studies$366,301
ZIA · FY2011 · CA · contact PI
Phase I and II Study of BCL Family Inhibitors in Lymphoma$244,201
ZIA · FY2011 · CA · contact PI
Phase II study of flavopiridol in mantle cell lymphoma and DLBCL$122,100
ZIA · FY2011 · CA · contact PI
BCR Signaling in ABC DLBCL$122,100
ZIA · FY2011 · CA · contact PI
Phase III Study of R-CHOP v DA-EPOCH-R with microarray$122,100
ZIA · FY2011 · CA · contact PI
Randomized Phase II study of borteozmibEPOCH-R in Mantle cell lymphoma$122,100
ZIA · FY2011 · CA · contact PI
Phase I study of bortezomib and DA-EPOCH-R with microarray in DLBCL$122,100
ZIA · FY2011 · CA · contact PI
Lymphoma Studies$349,579
ZIA · FY2010 · CA · contact PI
Phase III study of BCL-family inhibitors in lymphoma$233,053
ZIA · FY2010 · CA · contact PI
BCR Signaling in ABC DLBCL$116,526
ZIA · FY2010 · CA · contact PI
Phase III Study of R-CHOP v DA-EPOCH-R with microarray$116,526
ZIA · FY2010 · CA · contact PI
Randomized Phase II study of borteozmibEPOCH-R in Mantle cell lymphoma$116,526
ZIA · FY2010 · CA · contact PI
Phase I study of bortezomib and DA-EPOCH-R with microarray in DLBCL$116,526
ZIA · FY2010 · CA · contact PI
Phase II study of flavopiridol in mantle cell lymphoma and DLBCL$116,526
ZIA · FY2010 · CA · contact PI
Lymphoma Studies$358,868
ZIA · FY2009 · CA · contact PI
Phase I/II study of BCL-family inhibitors in lymphoma$239,245
ZIA · FY2009 · CA · contact PI
Phase II study of flavopiridol in mantle cell lymphoma and DLBCL$239,245
ZIA · FY2009 · CA · contact PI
Phase III Study of R-CHOP v DA-EPOCH-R with microarray$119,623
ZIA · FY2009 · CA · contact PI
Randomized Phase II study of borteozmibEPOCH-R in Mantle cell lymphoma$119,623
ZIA · FY2009 · CA · contact PI
Phase I study of bortezomib and DA-EPOCH-R with microarray in DLBCL$119,623
ZIA · FY2009 · CA · contact PI
Lymphoma Studies$337,660
Z01 · FY2008 · CA · contact PI
Phase III study of BCL-family inhibitors in lymphoma$225,107
Z01 · FY2008 · CA · contact PI
Phase II study of flavopiridol in mantle cell lymphoma and DLBCL$225,107
Z01 · FY2008 · CA · contact PI
Randomized Phase II study of borteozmibEPOCH-R in Mantle cell lymphoma$112,553
Z01 · FY2008 · CA · contact PI
Phase I study of bortezomib and DA-EPOCH-R with microarray in DLBCL$112,553
Z01 · FY2008 · CA · contact PI
Phase III Study of R-CHOP v DA-EPOCH-R with microarray$112,553
Z01 · FY2008 · CA · contact PI
Lymphoma Studies$555,012
Z01 · FY2007 · CA · contact PI
Phase III Study of R-CHOP v DA-EPOCH-R with microarray$243,558
Z01 · FY2007 · CA · contact PI
Phase III study of BCL-family inhibitors in lymphoma$199,065
Z01 · FY2007 · CA · contact PI
Randomized Phase II study of borteozmibEPOCH-R in Mantle cell lymphoma$199,065
Z01 · FY2007 · CA · contact PI
Phase II study of flavopiridol in mantle cell lymphoma and DLBCL$199,065
Z01 · FY2007 · CA · contact PI
Phase I study of bortezomib and DA-EPOCH-R with microarray in DLBCL$154,572
Z01 · FY2007 · CA · contact PI
Lymphoma Studies$0
Z01 · FY2006 · SC · contact PI
Phase III Study of R-CHOP v DA-EPOCH-R with microarray$0
Z01 · FY2006 · BC · contact PI
Randomized Phase II study of borteozmibEPOCH-R in Mantle$0
Z01 · FY2006 · BC · contact PI
Phase I study of bortezomib and DA-EPOCH-R with microarr$0
Z01 · FY2006 · BC · contact PI
Phase III study of BCL-family inhibitors in lymphoma$0
Z01 · FY2006 · BC · contact PI
Phase II study of flavopiridol in mantle cell lymphoma a$0
Z01 · FY2006 · BC · contact PI
Lymphoma Studies$0
Z01 · FY2005 · SC
Lymphoma Studies$0
Z01 · FY2004 · SC
Lymphoma Studies$0
Z01 · FY2003 · SC
Lymphoma Studies$0
Z01 · FY2001 · SC
Lymphoma Studies$0
Z01 · FY2000 · SC